WASHINGTON — Democratic presidential candidates are making bigger promises than ever before on reforming the pharmaceutical industry.
But the candidates have not formulated the policies on their own. Instead, to workshop the bold and occasionally far-fetched ideas, Democrats have turned to a familiar cast of outside advisers, according to drug pricing advocates, Capitol Hill aides, and the campaigns themselves.
Three prominent members of the drug pricing brain trust who have counseled Democrats on the issue, the sources said, include Chris Jennings, a consultant who served in the Obama and Clinton administrations, and two Harvard professors: Richard Frank, a health economist, and Dr. Aaron Kesselheim, a professor of medicine and drug-pricing expert.
About the Author Reprints
